News
Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune responses against cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback